Varicella vaccination in Japan: Necessity of implementing a routine vaccination program

Journal of Infection and Chemotherapy

Volumn 19, Issue 2, 2013, Pages 188-195

  Ozaki, Takao ^a  

^a Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

Author keywords

Breakthrough varicella; Oka strain; Routine vaccination program; Two dose vaccination schedule; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ANTIBODY TITER; CHICKENPOX; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MARKETING; DRUG SAFETY; DRUG USE; HEALTH CARE DISTRIBUTION; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INFECTION RATE; JAPAN; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINATION REACTION; VIRUS STRAIN;

EID: 84880698480     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0577-x     Document Type: Review

References (49)

1. Ozaki T, Kajita Y, Asano Y, Aono T, Yamanishi K. Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol. 1994;44:263-5.
2. Ozaki T, Ichikawa T, Matsui Y, Nagai T, Asano Y, Yamanishi K, et al. Viremic phase in nonimmunocompromised children with varicella. J Pediatr. 1984;104:85-7.
3. Asano Y, Itakura N, Hiroishi Y, Hirose S, Nagai T, Ozaki T, et al. Viremia is present in incubation period in nonimmunocompromised children with varicella. J Pediatr. 1985;106:69-71.
4. Ozaki T, Ichikawa T, Matsui Y, Kondo H, Nagai T, Asano Y, et al. Lymphocyte-associated viremia in varicella. J Med Virol. 1986;19:249-53.
5. Grose C. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics. 1981;68:735-7.
6. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med. 2004;200:917-25.
7. Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr. 2004;144:68-74.
8. Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med. 1994;330:901-5.
9. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2:1288-90.
10. WHO Experts Committee on Biological Standardization (1985) Requirements for varicella vaccine (live). Requirements for biological substances no. 36. WHO, Geneva, pp 102-133.
11. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol. 2002;76:11447-59.
12. Gomi Y, Ozaki T, Nishimura N, Narita A, Suzuki M, Ahn J, et al. DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine. 2008;26:5627-32.
13. Ozaki T, Masuda S, Asano Y, Kondo K, Namazue J, Yamanishi K. Investigation of varicella-zoster virus DNA by the polymerase chain reaction in healthy children with varicella vaccination. J Med Virol. 1994;42:47-51.
14. Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T, Takahashi M. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken J. 1982;25:43-5.
15. Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken J. 1975;18:35-40.
16. Ozaki T, Nagayoshi S, Morishima T, Isomura S, Suzuki S, Asano Y, et al. Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward. Biken J. 1978;21:69-72.
17. Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y, et al. Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken J. 1982;25:29-42.
18. Kamiya H, Kato T, Isaji M, Torigoe S, Oitani K, Ito M, et al. Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J. 1984;27:99-102.
19. Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine. 2003;21:3845-53.
20. Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine. 2000;18:2375-80.
21. CDC. National and state vaccination coverage among children aged 19-35 months - United States, 2010. MMWR. 2011;60:1157-63.
22. Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken J. 1984;27:39-42.
23. Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine. 2005;23:1205-8.
24. Kumagai T, Yamanaka T, Wataya Y, Umetsu A, Kawamura N, Ikeda K, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol. 1997;100:130-4.
25. Kumagai T, Ozaki T, Kamada M, Igarashi C, Yuri K, Furukawa H, et al. Gelatin-containing diphtheria-tetanus-pertussis (DTP) vaccine causes sensitization to gelatin in the recipients. Vaccine. 2000;18:1555-61.
26. Ozaki T, Nishimura N, Gotoh K, Kawabe S, Funahashi K, Shiraki K, et al. Utility of immune adherence hemagglutination method for antibody measurement of varicella vaccination. Kansenshogaku Zasshi. 2012;86:146-8. Japanese.
27. Ozaki T, Nagai H, Kimura T, Ichikawa T, Suzuki S, Kito H, et al. The age distribution of neutralizing antibodies against varicella-zoster virus in healthy individuals. Biken J. 1980;23:9-14.
28. Kamiya H, Asano Y, Ozaki T, Baba K, Kumagai T, Nagai T, et al. Varicella vaccine potency and stability during transport and delivery. Kansenshogaku Zasshi. 2011;85:161-5. (in Japanese).
29. Ozaki T, Nishimura N, Gotoh K, Funahashi K. A study for the necessity of virus titer of varicella vaccine presently used. Kansenshogaku Zasshi. 2012;86:749-54. (in Japanese).
30. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis. 1996;174(suppl 3):S310-3.
31. Takayama N, Minamitani M, Takayama M. High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn. 1997;39:663-8.
32. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997;278:1495-9.
33. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J. 1999;18:1047-50.
34. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-60.
35. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002;186:102-5.
36. Dworkin MS, Jennings CE, Roth-Thomas J, Lang JE, Stukenberg C, Lumpkin JR. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002;35:102-4.
37. Ozaki T, Morishima T, Hirota T, Sugiyama K, Asano Y. Pediatric admission for vaccine preventable diseases: a 5-year survey from 1994 to 1998 in Aichi Prefecture. Jpn J Infect Dis. 1999;52:208-13.
38. Sugawara T, Ohkusa Y, Oikawa K, Haneda N, Kikuchi K, Kato F, et al. Cost-effectiveness analysis of routine immunization for varicella in Japan. Kansenshogaku Zasshi. 2006;80:212-9. (in Japanese).
39. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
40. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305:160-6.
41. National Institute of Infectious Diseases. Fact sheet about varicella vaccine. 2010, p. 7-8 (in Japanese) http://www.mhlw.go.jp/stf/shingi/ 2r9852000000bx23-att/2r9852000000bxqx.pdf. Accessed 7 July 2010.
42. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356:1121-9.
43. Fine PEM, Mulholland K. Community immunity. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Amsterdam: Elsevier; 2013. p. 1395-412.
44. Gao Z, Gidding HF, Wood JG, MacIntyre CR. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiol Infect. 2010;138:457-68.
45. Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. 2011;203:312-5.
46. Kattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose vaccination on varicella epidemiology: Connecticut, 2005-2008. J Infect Dis. 2011;203:509-12.
47. Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines co-administered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. Pediatr Infect Dis J 2012 (Epub ahead of print).
48. Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Centers for Disease Control and Prevention. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12.
49. Committee on Infectious Diseases. Policy statement. Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics. 2011;128:630-2.